The global leader in developing LAG-3 therapeutics
BioCentury 25th Annual NewsMakers in the Biotech Industry Conference New York 7th September 2018
• Globally active biotechnology company with operations in Australia, Europe and U.S.
• Four LAG-3 related product candidates in development in immuno-oncology and autoimmune disease
• Committed partnerships with three of the world’s largest pharmaceutical companies - Merck (MSD), Novartis and GSK, along with Eddingpharm in China
• Backed by high profile institutional healthcare investors: Platinum Asset Management and Australian Ethical in Australia, along with Ridgeback Capital in the U.S.
• Meaningful clinical, regulatory, and corporate news flow throughout calendar 2018 and 2019
To view Presentation please download PDF attached:
Download this document